
Lars F Iversen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8050659/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. British Journal of Dermatology, 2009, 160, 319-324.	1.5	303
2	The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nature Immunology, 2008, 9, 1028-1036.	14.5	297
3	Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. British Journal of Dermatology, 2015, 172, 244-252.	1.5	239
4	Modulation of Keratinocyte Gene Expression and Differentiation by PPAR-Selective Ligands and Tetradecylthioacetic Acid. Journal of Investigative Dermatology, 2001, 116, 702-712.	0.7	213
5	Old and New Biological Therapies for Psoriasis. International Journal of Molecular Sciences, 2017, 18, 2297.	4.1	179
6	The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. British Journal of Dermatology, 2005, 152, 37-42.	1.5	177
7	Cardiovascular outcomes and systemic antiâ€inflammatory drugs in patients with severe psoriasis: 5â€year followâ€up of a Danish nationwide cohort. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1128-1134.	2.4	164
8	Protein Expression of TNF-α in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 2. Journal of Immunology, 2006, 176, 1431-1438.	0.8	130
9	Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. British Journal of Dermatology, 2015, 172, 1395-1406.	1.5	127
10	Malignant inflammation in cutaneous Tâ€cell lymphoma—a hostile takeover. Seminars in Immunopathology, 2017, 39, 269-282.	6.1	110
11	Expression and Localization of Peroxisome Proliferator-Activated Receptors and Nuclear Factor κB in Normal and Lesional Psoriatic Skin. Journal of Investigative Dermatology, 2003, 121, 1104-1117.	0.7	105
12	Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108Âweeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). Journal of the American Academy of Dermatology, 2017, 77, 855-862.	1.2	104
13	Longâ€ŧerm efficacy and safety of tildrakizumab for moderateâ€ŧoâ€₅evere psoriasis: pooled analyses of two randomized phase <scp>III</scp> clinical trials (re <scp>SURFACE</scp> 1 and re <scp>SURFACE</scp> 2) through 148 weeks. British Journal of Dermatology, 2020, 182, 605-617.	1.5	103
14	The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. British Journal of Dermatology, 2005, 153, 911-918.	1.5	101
15	The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine, 2008, 41, 16-23.	3.2	98
16	ll̂ºBζ is a key driver in the development of psoriasis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5825-33.	7.1	95
17	Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis. American Journal of Medicine, 2015, 128, 1325-1334.e2.	1.5	94
18	Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood, 2019, 134, 1072-1083.	1.4	94

#	Article	IF	CITATIONS
19	Studies of <scp>J</scp> ak/ <scp>STAT</scp> 3 expression and signalling in psoriasis identifies <scp>STAT</scp> 3â€ <scp>S</scp> er727 phosphorylation as a modulator of transcriptional activity. Experimental Dermatology, 2013, 22, 323-328.	2.9	86
20	Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood, 2016, 127, 1287-1296.	1.4	86
21	The Activity of Caspase-1 Is Increased in Lesional Psoriatic Epidermis. Journal of Investigative Dermatology, 2007, 127, 2857-2864.	0.7	80
22	STAT1 expression and activation is increased in lesional psoriatic skin. British Journal of Dermatology, 2013, 168, 302-310.	1.5	78
23	Single-cell heterogeneity in Sézary syndrome. Blood Advances, 2018, 2, 2115-2126.	5.2	78
24	Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Oncotarget, 2015, 6, 20555-20569.	1.8	78
25	Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatology, 2016, 16, 15.	2.1	77
26	Clinical use of dimethyl fumarate in moderateâ€ŧoâ€severe plaqueâ€ŧype psoriasis: a European expert consensus. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 3-14.	2.4	76
27	Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis. JAMA Dermatology, 2016, 152, 1114.	4.1	75
28	1?,25(OH)2D3 regulates NF-?B DNA binding activity in cultured normal human keratinocytes through an increase in I?B? expression. Archives of Dermatological Research, 2004, 296, 195-202.	1.9	66
29	Bacterial Toxins Fuel Disease Progression in Cutaneous T-Cell Lymphoma. Toxins, 2013, 5, 1402-1421.	3.4	66
30	Low-Dose (10-Gy) Total Skin Electron Beam Therapy for Cutaneous T-Cell Lymphoma: An Open Clinical Study and Pooled Data Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 92, 138-143.	0.8	64
31	Clinical Goals and Barriers to Effective Psoriasis Care. Dermatology and Therapy, 2019, 9, 5-18.	3.0	63
32	Systematic review of machine learning for diagnosis and prognosis in dermatology. Journal of Dermatological Treatment, 2020, 31, 496-510.	2.2	62
33	Caspase-5 Expression Is Upregulated in Lesional Psoriatic Skin. Journal of Investigative Dermatology, 2011, 131, 670-676.	0.7	61
34	Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood, 2014, 124, 761-770.	1.4	59
35	Mitogen- and Stress-Activated Protein Kinase 1 Is Activated in Lesional Psoriatic Epidermis and Regulates the Expression of Pro-Inflammatory Cytokines. Journal of Investigative Dermatology, 2006, 126, 1784-1791.	0.7	58
36	Kinetics and differential expression of the skin-related chemokines CCL27 and CCL17 in psoriasis, atopic dermatitis and allergic contact dermatitis. Experimental Dermatology, 2011, 20, 789-794.	2.9	58

#	Article	IF	CITATIONS
37	Linoleic acid and dihomogammalinolenic acid inhibit leukotriene B4 formation and stimulate the formation of their 15-lipoxygenase products by human neutrophilsin vitro. Evidence of formation of antiinflammatory compounds. Agents and Actions, 1991, 33, 286-291.	0.7	57
38	Tumor necrosis factor-α-induced CTACK/CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor κB. Cytokine, 2005, 29, 49-55.	3.2	57
39	Dimethylfumarate Specifically Inhibits the Mitogen and Stress-Activated Kinases 1 and 2 (MSK1/2): Possible Role for its Anti-Psoriatic Effect. Journal of Investigative Dermatology, 2007, 127, 2129-2137.	0.7	57
40	Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFI± therapy. British Journal of Dermatology, 2010, 163, 1194-1204.	1.5	57
41	1α,25-Dihydroxyvitamin D3 Stimulates Activator Protein 1 DNA-Binding Activity by a Phosphatidylinositol 3-Kinase/Ras/MEK/Extracellular Signal Regulated Kinase 1/2 and c-Jun N-Terminal Kinase 1-Dependent Increase in c-Fos, Fra1, and c-Jun Expression in Human Keratinocytes. Journal of Investigative Dermatology. 2003. 120. 561-570.	0.7	55
42	MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. Anticancer Research, 2014, 34, 7207-17.	1.1	55
43	Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. Blood, 2018, 131, 759-770.	1.4	54
44	Inverse Regulation of the Nuclear Factor-κB Binding to the p53 and Interleukin-8 κB Response Elements in Lesional Psoriatic Skin. Journal of Investigative Dermatology, 2005, 124, 1284-1292.	0.7	53
45	IL-20 Gene Expression Is Induced by IL-1β through Mitogen-Activated Protein Kinase and NF-κB-Dependent Mechanisms. Journal of Investigative Dermatology, 2007, 127, 1326-1336.	0.7	52
46	Tumor Necrosis Factor α-Mediated Induction of Interleukin 17C in Human Keratinocytes Is Controlled by Nuclear Factor κB. Journal of Biological Chemistry, 2011, 286, 25487-25494.	3.4	51
47	Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenomics Journal, 2018, 18, 494-500.	2.0	51
48	STAT5 induces miR-21 expression in cutaneous T cell lymphoma. Oncotarget, 2016, 7, 45730-45744.	1.8	45
49	Inflammatory Cytokines Break Down Intrinsic Immunological Tolerance of Human Primary Keratinocytes to Cytosolic DNA. Journal of Immunology, 2014, 192, 2395-2404.	0.8	44
50	High-throughput RNA sequencing from paired lesional- and non-lesional skin reveals major alterations in the psoriasis circRNAome. BMC Medical Genomics, 2019, 12, 174.	1.5	43
51	Aldara [®] -induced skin inflammation: studies of patients with psoriasis. British Journal of Dermatology, 2015, 172, 345-353.	1.5	42
52	Effect of dihomogammalinolenic acid and its 15-lipoxygenase metabolite on eicosanoid metabolism by human mononuclear leukocytes in vitro: selective inhibition of the 5-lipoxygenase pathway. Archives of Dermatological Research, 1992, 284, 222-226.	1.9	41
53	Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis. British Journal of Dermatology, 2017, 176, 732-740.	1.5	41
54	Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting. Acta Dermato-Venereologica, 2017, 97, 426-432.	1.3	41

#	Article	IF	CITATIONS
55	Characterization of TNF-α– and IL-17A–Mediated Synergistic Induction ofÂDEFB4 Gene Expression in Human Keratinocytes through llੰºBζ. Journal of Investigative Dermatology, 2016, 136, 1608-1616.	0.7	40
56	Secukinumab treatment in newâ€onset psoriasis: aiming to understand the potential for disease modification – rationale and design of the randomized, multicenter <scp>STEPI</scp> n study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1930-1939.	2.4	40
57	Signal transduction pathways in human epidermis. European Journal of Dermatology, 2005, 15, 4-12.	0.6	40
58	1α,25-Dihydroxyvitamin D3 Induced Differentiation of Cultured Human Keratinocytes is Accompanied by a PKC-Independent Regulation of AP-1 DNA Binding Activity. Journal of Investigative Dermatology, 2000, 114, 1174-1179.	0.7	38
59	Proâ€inflammatory cytokine release in keratinocytes is mediated through the MAPK signalâ€integrating kinases. Experimental Dermatology, 2008, 17, 498-504.	2.9	38
60	SATB1 in Malignant T Cells. Journal of Investigative Dermatology, 2018, 138, 1805-1815.	0.7	38
61	Reduced Oxazolone-Induced Skin Inflammation in MAPKAP Kinase 2 Knockout Mice. Journal of Investigative Dermatology, 2009, 129, 891-898.	0.7	36
62	MK2 regulates the early stages of skin tumor promotion. Carcinogenesis, 2009, 30, 2100-2108.	2.8	35
63	Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression. Inflammation Research, 2011, 60, 643-653.	4.0	35
64	The p38 MAPK Regulates IL-24 Expression by Stabilization of the 3′ UTR of IL-24 mRNA. PLoS ONE, 2010, 5, e8671.	2.5	35
65	Mitogen- and Stress-Activated Protein Kinase 2 and Cyclic AMP Response Element Binding Protein are Activated in Lesional Psoriatic Epidermis. Journal of Investigative Dermatology, 2007, 127, 2012-2019.	0.7	34
66	<scp>TNFα</scp> â€and <scp>IL</scp> â€17Aâ€mediated S100 <scp>A</scp> 8 expression is regulated by p38 <scp>MAPK</scp> . Experimental Dermatology, 2013, 22, 476-481.	2.9	34
67	Changes in <scp>mRNA</scp> expression precede changes in micro <scp>RNA</scp> expression in lesional psoriatic skin during treatment with adalimumab. British Journal of Dermatology, 2015, 173, 436-447.	1.5	34
68	Localization of treatmentâ€resistant areas in patients with psoriasis on biologics. British Journal of Dermatology, 2019, 181, 332-337.	1.5	34
69	Human epidermis transforms exogenous leukotriene A4 into peptide leukotrienes: possible role in transcellular metabolism. Archives of Dermatological Research, 1994, 286, 261-267.	1.9	32
70	Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin. British Journal of Dermatology, 2004, 151, 600-607.	1.5	32
71	Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4 ⁺ T cells in cutaneous T-cell lymphoma. Oncolmmunology, 2019, 8, e1641387.	4.6	32
72	Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics. Psoriasis: Targets and Therapy, 2021, Volume 11, 83-97.	2.2	32

#	Article	IF	CITATIONS
73	Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement. British Journal of Dermatology, 2010, 162, 1216-1223.	1.5	31
74	Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. International Journal of Dermatology, 2014, 53, e464-6.	1.0	31
75	IL-8 and p53 are inversely regulated through JNK, p38 and NF-ήB p65 in HepG2 cells during an inflammatory response. Inflammation Research, 2008, 57, 329-339.	4.0	30
76	Inflammasomes and inflammatory caspases in skin inflammation. Expert Review of Molecular Diagnostics, 2008, 8, 697-705.	3.1	30
77	Mice Lacking MSK1 and MSK2 Show Reduced Skin Tumor Development in a Two-Stage Chemical Carcinogenesis Model. Cancer Investigation, 2011, 29, 240-245.	1.3	30
78	Leptin deficiency in mice counteracts imiquimod (IMQ)â€induced psoriasisâ€like skin inflammation while leptin stimulation induces inflammation in human keratinocytes. Experimental Dermatology, 2017, 26, 338-345.	2.9	30
79	IL-20, IL-21 and p40: Potential Biomarkers of Treatment Response for Ustekinumab. Acta Dermato-Venereologica, 2013, 93, 150-155.	1.3	29
80	Psoriasis and Risk of Mental Disorders in Denmark. JAMA Dermatology, 2019, 155, 745.	4.1	29
81	Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases. Nature Communications, 2018, 9, 4344.	12.8	28
82	MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas. Cancers, 2020, 12, 1229.	3.7	28
83	STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes. PLoS ONE, 2017, 12, e0176994.	2.5	27
84	Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the International Psoriasis Council. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1115-1119.	2.4	25
85	Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: AÂDanish nationwide, population-based cohort study. Journal of the American Academy of Dermatology, 2014, 71, 529-535.	1.2	24
86	Hospital-diagnosed atopic dermatitis and long-term risk of myocardial infarction: a population-based follow-up study. BMJ Open, 2016, 6, e011870.	1.9	24
87	Investigating heredity in cutaneous T-cell lymphoma in a unique cohort of Danish twins. Blood Cancer Journal, 2017, 7, e517-e517.	6.2	24
88	<scp>IL</scp> â€17F regulates psoriasisâ€associated genes through lκBζ. Experimental Dermatology, 2017, 26, 234-241.	2.9	24
89	Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). Archives of Dermatological Research, 2019, 311, 351-360.	1.9	24
90	lκBζ is a key player in the antipsoriatic effects of secukinumab. Journal of Allergy and Clinical Immunology, 2020, 145, 379-390.	2.9	24

#	Article	IF	CITATIONS
91	<i>Staphylococcus aureus</i> alpha-toxin inhibits CD8 ⁺ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma. Oncolmmunology, 2020, 9, 1751561.	4.6	24
92	Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome. Blood Cancer Journal, 2020, 10, 57.	6.2	24
93	Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis. JAMA Dermatology, 2021, 157, 676.	4.1	24
94	Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict. Dermatology and Therapy, 2016, 6, 273-285.	3.0	23
95	Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). Journal of the European Academy of Dermatology and Venereology, 2019, 33, 340-354.	2.4	23
96	Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: a multiâ€centre cohort study. Journal of Internal Medicine, 2021, 290, 693-703.	6.0	23
97	Immune responses and parasitological observations induced during probiotic treatment with medicinal Trichuris suis ova in a healthy volunteer. Immunology Letters, 2017, 188, 32-37.	2.5	22
98	Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderateâ€toâ€severe plaque psoriasis – nationwide results from the <scp>DERMBIO</scp> registry. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1183-1187.	2.4	21
99	Reformulations of wellâ€known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1271-1284.	2.4	21
100	The human <scp>IL</scp> â€17A/F heterodimer regulates psoriasisâ€associated genes through lκBζ. Experimental Dermatology, 2018, 27, 1048-1052.	2.9	21
101	Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments. Journal of Dermatological Treatment, 2019, 30, 311-319.	2.2	21
102	Deep Learning for Diagnostic Binary Classification of Multiple-Lesion Skin Diseases. Frontiers in Medicine, 2020, 7, 574329.	2.6	20
103	The role of mitogen―and stressâ€activated protein kinase 1 and 2 in chronic skin inflammation in mice. Experimental Dermatology, 2011, 20, 140-145.	2.9	19
104	Interleukin 20 regulates dendritic cell migration and expression of co-stimulatory molecules. Molecular and Cellular Therapies, 2016, 4, 1.	0.2	19
105	HSP90 inhibitor RCRNâ€305 for oral treatment of plaqueâ€type psoriasis: efficacy, safety and biomarker results in an openâ€label proofâ€ofâ€concept study*. British Journal of Dermatology, 2022, 186, 861-874.	1.5	19
106	Clobal reporting of cases of COVIDâ€19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. British Journal of Dermatology, 2020, 183, 404-406.	1.5	18
107	IL-37 Expression Is Downregulated in Lesional Psoriasis Skin. ImmunoHorizons, 2020, 4, 754-761.	1.8	18
108	Prevalence and characterization of treatmentâ€refractory psoriasis and superâ€responders to biologic treatment: a nationwide study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1284-1291.	2.4	18

#	Article	IF	CITATIONS
109	Purification and characterization of leukotriene A4hydrolase from human epidermis. FEBS Letters, 1995, 358, 316-322.	2.8	17
110	Upregulation of Nuclear PKC and MAP-Kinase During Hyperproliferation of Guinea Pig Epidermis: Modulation by 13-(S)-Hydroxyoctadecadienoic Acid (13-HODE). Cellular Signalling, 1998, 10, 143-149.	3.6	17
111	The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in mice. EMBO Journal, 2009, 28, 2449-2460.	7.8	17
112	Tumour necrosis factor-α plays a significant role in the Aldara-induced skin inflammation in mice. British Journal of Dermatology, 2016, 174, 1011-1021.	1.5	17
113	The expression and phosphorylation of eukaryotic initiation factor 4E are increased in lesional psoriatic skin. British Journal of Dermatology, 2009, 161, 1059-1066.	1.5	16
114	Patient-relevant needs and treatment goals in nail psoriasis. Quality of Life Research, 2016, 25, 1179-1188.	3.1	16
115	Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1188-1195.	2.4	16
116	Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. Acta Dermato-Venereologica, 2018, 99, 18-25.	1.3	16
117	Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2225-2238.	2.4	16
118	The expression of dual-specificity phosphatase 1 mRNA is downregulated in lesional psoriatic skin. British Journal of Dermatology, 2013, 168, 339-345.	1.5	15
119	Comparative Analysis of Two Gene-Targeting Approaches Challenges the Tumor-Suppressive Role of the Protein Kinase MK5/PRAK. PLoS ONE, 2015, 10, e0136138.	2.5	15
120	The role of leptin in psoriasis comprises a proinflammatory response by the dermal fibroblast. British Journal of Dermatology, 2016, 174, 187-190.	1.5	15
121	Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment. Autoimmunity Reviews, 2021, 20, 102731.	5.8	15
122	The HSP90 inhibitor RGRNâ€305 exhibits strong immunomodulatory effects in human keratinocytes. Experimental Dermatology, 2021, 30, 773-781.	2.9	15
123	Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5‒Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2021, 141, 2449-2458.	0.7	15
124	<scp>TRIM</scp> 21 is important in the early phase of inflammation in the imiquimodâ€induced psoriasisâ€like skin inflammation mouse model. Experimental Dermatology, 2017, 26, 713-720.	2.9	13
125	Effect of Dead Sea Climatotherapy on Psoriasis; A Prospective Cohort Study. Frontiers in Medicine, 2020, 7, 83.	2.6	13
126	CCL27 expression is regulated by both p38 MAPK and IKKβ signalling pathways. Cytokine, 2011, 56, 699-707.	3.2	12

#	Article	IF	CITATIONS
127	Role of p38 Mitogen-activated Protein Kinase Isoforms in Murine Skin Inflammation Induced by 12-O-tetradecanoylphorbol 13-acetate. Acta Dermato-Venereologica, 2011, 91, 271-278.	1.3	12
128	Malignant T cells activate endothelial cells via IL-17 F. Blood Cancer Journal, 2017, 7, e586-e586.	6.2	12
129	Psoriasis and risk of myocardial infarction before and during an era with biological therapy: a populationâ€based followâ€up study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2185-2190.	2.4	12
130	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology, 2022, 158, 561.	4.1	12
131	Incorporation of 15-hydroxyeicosatrienoic acid in specific phospholipids of cultured human keratinocytes and psoriatic plaques. Experimental Dermatology, 1995, 4, 74-78.	2.9	11
132	Interleukin 20 protein locates to distinct mononuclear cells in psoriatic skin. Experimental Dermatology, 2014, 23, 349-351.	2.9	11
133	Langerhans cell markers <scp>CD</scp> 1a and <scp>CD</scp> 207 are the most rapidly responding genes in lesional psoriatic skin following adalimumab treatment. Experimental Dermatology, 2017, 26, 804-810.	2.9	11
134	Early efficacy and safety data with fixedâ€dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 5-9.	2.4	11
135	Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-α. PLoS ONE, 2016, 11, e0167437.	2.5	11
136	<i>Staphylococcus aureus</i> and Antibiotics in Cutaneous T-Cell Lymphoma. Dermatology, 2022, 238, 551-553.	2.1	11
137	Distribution of monohydroxy fatty acids in specific human epidermal phospholipids. Experimental Dermatology, 1993, 2, 38-44.	2.9	10
138	LTA4 hydrolase in human skin: decreased activity, but normal concentration in lesional psoriatic skin. Archives of Dermatological Research, 1996, 288, 217-224.	1.9	10
139	Concerns related to the coronavirus disease 2019 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e773-e776.	2.4	10
140	Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab. Journal of Dermatological Treatment, 2022, 33, 2503-2509.	2.2	10
141	Comorbidity in Adult Psoriasis: Considerations for the Clinician. Psoriasis: Targets and Therapy, 0, Volume 12, 139-150.	2.2	10
142	The effect of botulinum neurotoxin A in patients with plaque psoriasis – an exploratory trial. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e81-e82.	2.4	9
143	Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars. Expert Opinion on Biological Therapy, 2021, 21, 75-80.	3.1	9
144	Tissue-Resident Memory T Cells in Skin Diseases: A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 9004.	4.1	9

Lars F Iversen

#	Article	IF	CITATIONS
145	Non-random Plaque-site Recurrence of Psoriasis in Patients Treated with Dead Sea Climatotherapy. Acta Dermato-Venereologica, 2019, 99, 909-910.	1.3	9
146	A characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis. Dermatology Reports, 2010, 2, 14.	0.8	8
147	The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma. Dermatology, 2021, 237, 283-290.	2.1	8
148	MicroRNA-93 Targets p21 and Promotes Proliferation in Mycosis Fungoides T Cells. Dermatology, 2021, 237, 277-282.	2.1	8
149	Effectiveness of interdisciplinary combined dermatology–gastroenterology–rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial. BMJ Open, 2021, 11, e041871.	1.9	8
150	Longâ€ŧerm efficacy and safety of brodalumab in moderateâ€ŧoâ€severe plaque psoriasis: a post hoc pooled analysis of AMAGINEâ€2 and â€3. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1275-1283.	2.4	8
151	MicroRNA normalization candidates for quantitative reverse-transcriptase polymerase chain reaction in real time in lesional and nonlesional psoriatic skin. British Journal of Dermatology, 2013, 169, 677-681.	1.5	7
152	Effectiveness of brodalumab after previous treatment failure of interleukin― <scp>17A</scp> inhibitors in patients with psoriasis. Dermatologic Therapy, 2021, 34, e15106.	1.7	7
153	Protein phosphatase 2Cδ/Wip1 regulates phospho-p90RSK2 activity in lesional psoriatic skin. Journal of Inflammation Research, 2017, Volume 10, 169-180.	3.5	6
154	Diagnostic Two-Gene Classifier in Early-Stage Mycosis Fungoides: A Retrospective MulticenterÂStudy. Journal of Investigative Dermatology, 2021, 141, 213-217.e5.	0.7	6
155	Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites. Journal of Dermatological Treatment, 2021, 32, 916-921.	2.2	6
156	Anti-inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse models. BMC Immunology, 2013, 14, 51.	2.2	5
157	Disease activity in and quality of life of patients with psoriatic arthritis mutilans: the Nordic PAM Study. Scandinavian Journal of Rheumatology, 2017, 46, 454-460.	1.1	5
158	Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study. Journal of the American Academy of Dermatology, 2018, 78, 1077-1083.e4.	1.2	5
159	<p>Dimethyl Fumarate Targets MSK1, RSK1, 2 and IKKα/Î ² Kinases and Regulates NF-I [®] B /p65 Activation in Psoriasis: A Demonstration of the Effect on Peripheral Blood Mononuclear Cells, Drawn from Two Patients with Severe Psoriasis Before and After Treatment with Dimethyl Fumarate. Psoriasis: Targets and Therapy, 2020. Volume 10, 1-11.	2.2	5
160	IkBζ is a Key Regulator of Tumour Necrosis Factor-a and Interleukin-17A-mediated Induction of Interleukin-36g in Human Keratinocytes. Acta Dermato-Venereologica, 2021, 101, adv00386.	1.3	5
161	Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab. JAMA Dermatology, 0, , .	4.1	5
162	Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5–15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials. Dermatolo Therapy, 2020, 10, 1111-1120.	gyaaod	4

#	Article	IF	CITATIONS
163	Suppressed microRNAâ€195â€5p expression in mycosis fungoides promotes tumor cell proliferation. Experimental Dermatology, 2020, 30, 1141-1149.	2.9	4
164	Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans—Results From the Nordic PAM Study. Frontiers in Medicine, 2021, 8, 629741.	2.6	4
165	Radiographic development during three decades in a patient with psoriatic arthritis mutilans. Acta Radiologica Open, 2015, 4, 205846011558809.	0.6	3
166	Pemphigus Vulgaris: Short Time to Relapse in Patients Treated in a Danish Tertiary Referral Center. Frontiers in Medicine, 2019, 6, 259.	2.6	3
167	Radiographic scoring systems for psoriatic arthritis are insufficient for psoriatic arthritis mutilans: results from the Nordic PAM Study. Acta Radiologica Open, 2020, 9, 205846012092079.	0.6	3
168	I-Kappa-B-Zeta Regulates Interleukin-17A/Tumor Necrosis Factor-Alpha Mediated Synergistic Induction of Interleukin-19 and Interleukin-20 in Humane Keratinocytes. Annals of Dermatology, 2021, 33, 122.	0.9	3
169	Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study. Blood, 2019, 134, 5300-5300.	1.4	3
170	Using FDC-PET/CT to Detect Vascular Inflammation in Patients with Psoriasis: Where to Look? And for What??. Journal of Investigative Dermatology, 2017, 137, 2236-2237.	0.7	2
171	Climatotherapy at the Dead Sea for psoriasis is a highly effective antiâ€inflammatory treatment in the short term: AnAimmunohistochemical study. Experimental Dermatology, 2022, , .	2.9	2
172	Quantification of Immunohistochemically Stained Cells in Skin Biopsies. Dermatopathology (Basel,) Tj ETQq0 0 C) rgBT /Ove 1.5	erlock 10 Tf 5
173	Cyclosporin A down-regulates the LTA4 hydrolase level in human keratinocyte cultures Acta Dermato-Venereologica, 1996, 76, 424-428.	1.3	2
174	346 IL-17F regulates psoriasis-associated genes through lÎ⁰Bζ. Journal of Investigative Dermatology, 2016, 136, S220.	0.7	1
175	The role of leukotriene A4 hydrolase/aminopeptidase in transcellular leukotriene B4 synthesis in human epidermis. Acta Dermato-venereologica Supplementum, 1997, 199, 1-28.	0.0	1
176	HLA-B*27 is significantly enriched in Nordic patients with psoriatic arthritis mutilans. Clinical and Experimental Rheumatology, 2021, 39, 775-780.	0.8	1
177	Growth medium-dependent ERK1/2 and AP-1 activity in cultured normal human keratinocytes modulates 1?,25-dihydroxyvitamin D3-induced differentiation. Archives of Dermatological Research, 2003, 295, 199-202.	1.9	0
178	Comment on †Tumour necrosis factorâ€Î± plays a significant role in the Aldaraâ€induced skin inflammation in mice': reply from authors. British Journal of Dermatology, 2016, 174, 1419-1420.	1.5	0
179	Letter by Hjuler et al Regarding Article, "Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Studyâ€: Circulation, 2018, 137, 1090-1091.	1.6	0
180	P3624Prevalence and severity of coronary artery disease linked to prognosis in psoriasis patients referred for coronary computed tomography angiography: A multicentre cohort study. European Heart Journal, 2019, 40, .	2.2	0

#	Article	IF	CITATIONS
181	Investigating the Role of I Kappa B Kinase ε in the Pathogenesis of Psoriasis. Acta Dermato-Venereologica, 2019, 99, 1035-1036.	1.3	Ο